Merck Kgaa Dm 5 (MKGAF) 107.3000 $MKGAF Forget Mylan,

New Post Public Reply Private Reply Replies (0) Message Board

Sep 19, 2016 at 7:11 PM

Merck Kgaa Dm 5 (MKGAF) 107.3000 $MKGAF

Forget Mylan, Buy These 3 Drug Stocks Instead
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 1:44PM CDT
With Mylan under pricing scrutiny, investors should focus on these top-ranked drug stocks now.
LCI: 32.48 (-0.10), ENDP: 20.06 (-0.79), VRX: 27.10 (-0.18), BSTC: 41.82 (-0.94), MYL: 41.49 (-0.30), TEVA: 50.70 (-1.04), USNA: 135.49 (-0.71)

Mylan (MYL) Draws Flak for Over Pricing EpiPen, Stock Down
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 6:41AM CDT
Mylan's (MYL) shares took a beating after U.S. senators raised questions about the company's massive price hike of epinephrine auto-injector, EpiPen.
ANIP: 63.75 (-0.55), MYL: 41.49 (-0.30), SNY: 38.70 (+0.27)

Intrexon (XON) Reports Wider Loss in Q2, Revenues Increase
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 4:10PM CDT
Intrexon (XON) reported a loss of 42 cents per share in second-quarter 2016, compared to the year-ago figure of 37 cents.
ZIOP: 5.66 (+0.16), ANIP: 63.75 (-0.55), XON: 27.92 (+0.07)

Merck KGaA (MKGAF) Q2 Earnings Fall, Guides Up on Sales
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:39AM CDT
Merck KGaA (MKGAF) reported second-quarter 2016 earnings of 80 cents on sales of $4.3 billion.
BMRN: 98.11 (+1.25), PFE: 33.65 (-0.29), ANIK: 47.49 (+0.12)

Merck KGaA (MKGAF) Q2 Earnings Fall But View Raised
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 3:29AM CDT
Merck KGaA (MKGAF) second-quarter 2016 earnings per American Depositary Receipt (ADR) came in at 80 cents.

What's in Store for Merck KGaA (MKGAF) in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:06AM CDT
Merck KGaA (MKGAF) is scheduled to report second-quarter 2016 earnings results on Aug 4.
IPXL: 26.18 (+0.03), IRWD: 14.89 (-0.03), PFE: 33.65 (-0.29)

Merck KGaA's Q1 Earnings Increase Y/Y, Offers 2016 View
Zacks Equity Research - Zacks Investment Research - Fri May 20, 9:33AM CDT
Merck KGaA (MKGAF) reported first-quarter 2016 earnings of $1.50 on sales of $4 billion.
BMRN: 98.11 (+1.25), PFE: 33.65 (-0.29), BMY: 55.08 (-0.52)

Merck KGaA (MKGAF) Q1 Earnings Increased Y/Y
Zacks Equity Research - Zacks Investment Research - Thu May 19, 2:24AM CDT
Merck KGaA (MKGAF) first-quarter 2016 earnings per American Depositary Receipt (ADR) came in at $1.5.

Merck KGaA (MKGAF) Q1 Earnings: What Awaits the Stock?
Zacks Equity Research - Zacks Investment Research - Mon May 16, 7:38AM CDT
Merck KGaA (MKGAF) is scheduled to report its first-quarter 2016 earnings results on May 19.
AXON: 16.77 (+0.03), BMRN: 98.11 (+1.25), PFE: 33.65 (-0.29)

Intrexon (XON) Q1 Loss Wider than Expected, Revenues Miss
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:30AM CDT
Intrexon Corporation (XON) reported a wider-than-expected first-quarter 2016 loss of 32 cents per share.
FCSC: 0.82 (unch), ANIP: 63.75 (-0.55), XON: 27.92 (+0.07)

Pfizer & Merck KGaA Partner with Syndax for Ovarian Cancer
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 12:50PM CST
Pfizer (PFE) and Merck KGaA (MKGAF) teamed up with Syndax Pharmaceuticals to evaluate the avelumab/entinostat combination for ovarian cancer.
PFE: 33.65 (-0.29), HZNP: 19.12 (-0.16), ARNA: 1.69 (+0.03)

Pfizer/Merck KGaA Start Two Phase III Studies on Avelumab
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 3:30PM CST
Pfizer (PFE) and Merck KGaA announced the initiation of two phase III studies on avelumab for the treatment of ovarian cancer and urothelial cancer.
ACHN: 7.81 (-0.26), PFE: 33.65 (-0.29), ANIK: 47.49 (+0.12)

Pfizer/Merck KGaA Begin Two Phase III Studies on Avelumab
Zacks Equity Research - Zacks Investment Research - Thu Dec 10, 2:20PM CST
Pfizer (PFE) and Merck KGaA announced the initiation of two phase III studies on avelumab for the treatment of advanced or metastatic gastric/gastro-esophageal junction cancers.
ACHN: 7.81 (-0.26), PFE: 33.65 (-0.29), ANIK: 47.49 (+0.12)

Merck KGaA-Pfizer's Avelumab May Get Orphan Status in EU
Zacks Equity Research - Zacks Investment Research - Fri Nov 27, 1:40PM CST
Merck KGaA (MKGAF) and Pfizer (PFE) announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion for immunotherapy candidate, avelumab.
MRK: 61.33 (-0.95), PFE: 33.65 (-0.29), CORT: 5.99 (+0.23)

Pfizer's (PFE) Xalkori Positive in Another Phase III Study
Arpita Dutt - Zacks Investment Research - Thu Nov 19, 1:52PM CST
Pfizer's (PFE) Xalkori scored in another phase III study. The company also got breakthrough therapy status for avelumab.
AGN: 245.29 (+0.10), PFE: 33.65 (-0.29), LLY: 79.16 (+0.36)

Intrexon (XON) Reports Wider-than-Expected Loss in Q3
Zacks Equity Research - Zacks Investment Research - Tue Nov 10, 9:30AM CST
Intrexon Corporation (XON) reported third-quarter 2015 loss of 34 cents per share.
XON: 27.92 (+0.07), BXLT: 46.02 (-0.18), ANIK: 47.49 (+0.12)

Merck KGaA/Pfizer's Avelumab Gets Fast Track Status
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 1:50PM CDT
Merck KGaA (MKGAF) and Pfizer announced that avelumab received fast track status from the FDA for metastatic merkel cell carcinoma.
MRK: 61.33 (-0.95), PFE: 33.65 (-0.29), CORT: 5.99 (+0.23)

Merck KGaA's Pipeline on Track, Updates Key R&D Projects
Zacks Equity Research - Zacks Investment Research - Fri Oct 02, 3:40PM CDT
Merck KGaA (MKGAF) provided an update regarding the stages of development of its key immuno-oncology and oncology pipeline candidates.
ENDP: 20.06 (-0.79), PFE: 33.65 (-0.29), CORT: 5.99 (+0.23)

BioMarin (BMRN) to Acquire Rights to Phenylketonuria Drugs
Zacks Equity Research - Zacks Investment Research - Fri Oct 02, 3:10PM CDT
BioMarin (BMRN) announced that it has acquired all global rights to Kuvan and pegvaliase from Merck Serono, a division of Merck KGaA (MKGAF).
BMRN: 98.11 (+1.25), NVET: 4.20 (-0.01), REGN: 402.83 (-5.80)

Roche's Primary Progressive MS Drug Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Mon Sep 28, 3:20PM CDT
Roche (RHHBY) announced encouraging results from the phase III ORATORIO study on ocrelizumab for primary progressive multiple sclerosis.
PFE: 33.65 (-0.29), LLY: 79.16 (+0.36), NVS: 79.94 (+0.60)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Feeding Families Foundation Gains $121,500 for NYC Push

Holy smokes, here comes some good news in the nonprofit corners! Feeding Families Foundation just got a hefty $121,500 boost from the Association of Contracting Plumbers of the City of New York Inc. This ain't just some pocket change; it's a full-fledged lifeline that helps them keep on delivering meals to parents who are practically living at their kid’s hospital...

Inovonics Duress Card Enhances Safety for K-12 and Beyond

A New Dawn for Safety in Schools and More It's about time we talk about something more substantial than just beefing up security cameras or tightening door locks. Real-world problems require nimble solutions, and that's where Status Solutions steps in with the Inovonics Duress Card. It's not just another gadget; it's a lightweight, wrist-mounted lifeline designed to say,...

Robotics in Cleaning: 2026 Sees Double Adoption Rates

Cleaning Industry Eyes Robotic Solutions Amid Labor Squeeze In a twist that's got industry veterans nodding knowingly, the cleaning industry is tipping towards automation. The recent 2026 Building Service Contractor Market Study reveals a massive leap: 32% of building service contractors (BSCs) plan to embrace robotic floor equipment in the coming year. That's a...

Rosewood HK Tops Best Hotel List Again; Asia Shines

Holding the Crown: Rosewood Hong Kong's Triumph When a single hotel keeps nabbing the top spot in the world's most prestigious rankings, it's worth taking a closer look. That's exactly what's happening with Rosewood Hong Kong, crowned the world's best once more in 2026—its second consecutive year at the pinnacle according to The 50 Best Hotels. Defining Luxury on a...

NY Sheriffs' Court Battle: Immigration Policies Under Fire

Sheriffs Clash with State Over Immigration Policies In a tense showdown reminiscent of an old-time standoff, 15 New York county sheriffs have drawn their battle lines against the state’s capricious maneuvers by pushing a federal court to hit the brakes on Albany’s newly minted immigration rule. The so-called “Local Cops, Local Crimes Act” is catching serious heat,...

Cabot Wilds: Nova Scotia's Next Luxury Golf Haven

Breaking New Ground in Golf and Luxury Cabot and the Bragg family are cooking up something extraordinary in Cumberland County, Nova Scotia. The new luxury lifestyle and golf destination, Cabot Wilds, promises to be more than just a retreat—it's a bold statement on how to marry nature, luxury, and community. Set to open in late 2027, this expansive 2,500-acre resort will...

Postal Connections Expands with New Hillsboro Opening

Expanding Horizons in Hillsboro In the world of postal and office services, Annex Brands, Inc. is making headlines by launching yet another Postal Connections spot, this time planting its flag in the tech-centric town of Hillsboro, Oregon. Spearheaded by Jason Rautenkranz, this expansion is more than just another dot on a map—it's a strategic push into one of the...

TGI Fridays Unveils New 3 For All Menu Options

Hedging Bets on New Dining Strategies Oh, the restaurant battlefield—where one day you're the toast of the town, and the next, you're hustling to keep those seats filled. TGI Fridays, a name as synonymous with casual eats as long as I’ve been in this game, is rolling the dice with a new offering dubbed '3 For All.' Doesn't sound like your average meal deal either....

NOAA Taps ICEYE US for Game-Changing SAR Satellite Data

The Strategic Move to SAR Data Imagine this: You’re in the thick of a hurricane, where visibility goes out the window, and traditional satellite data chokes under the crushing weight of clouds and nightfall. That's the precise chaos ICEYE US is cutting through with its Synthetic Aperture Radar (SAR) technology. The latest scuttlebutt is that NOAA's getting cozy with...

Paula's Choice Elevates Skincare Game with New Campaign

Strategy Meets Skincare: Paula's Choice in the Spotlight Catch this: Paula's Choice just dropped a moisturizer, but it ain't just lotion. No, the Pro-Collagen Peptide Plumping Intensive Moisturizer is here with a punch. And they've got Hannah Waddingham, of 'Ted Lasso' fame, fronting a campaign that screams confidence. Now, that's a way to announce your move at the...